 |
|
A New Regimen of Interleukin 2 and Lymphokine-Activated Killer CellsEfficacy Without Significant Toxicity
Timothy J. Eberlein, MD;
Deric D. Schoof, PhD;
Sung-Eun Jung, MD;
David Davidson;
Barbara Gramolini, MT(ASCP);
Kathleen McGrath, RN;
Anthony Massaro;
Richard E. Wilson, MD
Arch Intern Med. 1988;148(12):2571-2576.
Abstract
• Adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer (LAK) cells has proved to be successful in the treatment of some patients with metastatic cancer, but not without a significant degree of associated toxic effects. The primary goal of this study was to substantially reduce the toxicity of this complex and expensive treatment, while maintaining or improving efficacy. To this end, 29 patients were treated with LAK cells in conjunction with a low-dose regimen of interleukin 2 and a prolonged period of administration following LAK cell infusion. This protocol resulted in a considerable reduction in toxicity, as compared with that described in previous studies, without compromising the efficacy. This study offers further confirmation that adoptive immunotherapy of metastatic cancer can be clinically beneficial to patients for whom no other effective therapy is presently available.
(Arch Intern Med 1988;148:2571-2576)
Author Affiliations
From the Division of Surgical Oncology, Department of Surgery, Brigham & Women's Hospital and Harvard Medical School, Boston.
Footnotes
Accepted for publication June 18, 1988.
Reprint requests to Brigham & Women's Hospital, 75 Francis St, Boston, MA 02115 (Dr Eberlein).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Successful Adoptive Cellular Immunotherapy Is Dependent on Induction of a Host Immune Response Triggered by Cytokine (IFN-{gamma} and Granulocyte/Macrophage Colony-Stimulating Factor) Producing Donor Tumor-Infiltrating Lymphocytes
Nagoshi et al.
J. Immunol. 1998;160:334-344.
ABSTRACT
| FULL TEXT
|
